Pencil Beam Scanning in Patients With Renal Tumors

  • End date
    Sep 30, 2024
  • participants needed
  • sponsor
    Children's Hospital of Philadelphia
Updated on 4 October 2022
beam radiation
renal neoplasm


This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.


Patients with renal tumors including Wilms and clear cell sarcoma of the kidney (CCSK) are treated with multimodality therapy which may include surgery, chemotherapy, and radiation. While long-term disease control is excellent, these patients remain at risk for early and late toxicities partially from radiation. There have been no significant changes to traditional photon radiation fields, which encompass the post-operative bed, anterior abdomen, and vertebral body. Proton beam radiation using pencil beam scanning, which is characterized by Bragg peak dose deposition and high conformality of dose to target regions, is ideally suited to treat the retroperitoneum. This pilot study evaluates pencil beam scanning proton therapy (PBS-PT) to:

  • result in low acute gastrointestinal toxicity in patients receiving radiation therapy for renal tumors as measured by laboratory evaluations, clinician-assessed, and patient reported health related quality of life outcomes
  • decrease the duration of radiation therapy
  • compare doses to organs at risk (OARs) using PBS-PT as compared to traditional photon fields

Condition Renal Tumor, Wilms Tumor
Treatment Proton beam radiation using pencil beam scanning
Clinical Study IdentifierNCT03810651
SponsorChildren's Hospital of Philadelphia
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Less than 30 years of age
Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including
Any patient with favorable histology (FH), stage III disease
Any patient with focal or diffuse anaplasia
Any patient with CCSK
The patient is a candidate for external beam radiotherapy based on standard of care
for treatment of Wilms tumor or CCSK

Exclusion Criteria

Prior radiotherapy to the region of the study cancer
Chemotherapy administered for diagnosis of Wilms tumor or CCSK
Pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note